- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01815736
Undersøgelse til evaluering af skift fra en TDF-holdig kombinationsbehandling til en TAF-holdig fast dosiskombination (FDC) hos virologisk undertrykte, HIV-1 positive deltagere
Et fase 3, åbent studie til evaluering af skift fra et TDF-holdigt kombinationsregime til et TAF-holdigt kombinations-singlet tablet-regime (STR) hos virologisk undertrykte, HIV-1-positive forsøgspersoner
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
New South Wales
-
Darlinghurst, New South Wales, Australien, 2010
- Holdsworth House Medical Practice
-
Darlinghurst, New South Wales, Australien, 2010
- East Sydney Doctors
-
Darlinghurst, New South Wales, Australien, 2010
- Taylor Square Private Clinic
-
Darlinghurst, New South Wales, Australien, 2010
- St Vincent's Hospital, Sydney
-
Surry Hills, New South Wales, Australien, 2010
- Albion Street Centre
-
-
Victoria
-
Carlton, Victoria, Australien, 3053
- Melbourne Sexual Health Clinic
-
Melbourne, Victoria, Australien, 3004
- Alfred Hospital
-
Melbourne, Victoria, Australien, 3068
- Northside Clinic
-
South Yarra, Victoria, Australien, 3141
- Prahran Market Clinic
-
-
-
-
-
Brussels, Belgien, 1000
- CHU Saint-Pierre University Hospital
-
Ghent, Belgien, 1070
- Hôpital Universitaire Erasme - ULB
-
-
-
-
-
Rio de Janeiro, Brasilien, 21040-360
- Instituto De Pesquisa Clinica Evandro Chagas - Fundação Oswaldo Cruz
-
Santo Andre, Brasilien, 09060-650
- Faculdade de Medicina do ABC
-
Sao Paulo, Brasilien, 01246-900
- São Paulo Secretaria da Saúde - Instituto De Infectologia Emilio Ribas
-
Sao Paulo, Brasilien, 04121-000
- São Paulo Secretaria da Saúde - Centro de Referência e Treinamento em DST/AIDS
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2C7
- Ubc Downtown I.D. Clinic
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1R9
- Winnipeg Regional Health Authority - Health Sciences Centre Winnipeg
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Ottawa Hospital
-
Toronto, Ontario, Canada, M4N 3M5
- SunnyBrook Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 1K2
- Maple Leaf Research
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network, Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H2L 5B1
- Clinique Medicale du Quartier Latin
-
Montreal, Quebec, Canada, H3A 1T1
- Clinique OPUS
-
Montreal, Quebec, Canada, H2L 4P9
- Clinique médicale l'Actuel
-
Montréal, Quebec, Canada, H2X 2P4
- McGill University Health Centre (MUHC) - Montral Chest Institute
-
-
-
-
-
Copenhagen, Danmark, 2100
- Epidemiklinikken 5112, Rigshospitalet
-
-
-
-
-
Brighton, Det Forenede Kongerige, BN2 1ES
- Brighton and Sussex University Hospitals NHS Trust
-
London, Det Forenede Kongerige, E1 1BB
- Barts and the London NHS Trust
-
London, Det Forenede Kongerige, SW17 0QT
- Courtyard Clinic, St. Georges Hospital
-
London, Det Forenede Kongerige, SW10 9NH
- Chelsea and Westminster Hospital Foundation Trust
-
Manchester, Det Forenede Kongerige, M8 5RB
- North Manchester General Hospital
-
-
-
-
-
Santo Domingo, Dominikanske republik
- Instituto Dominicano de Estudios Virologicos - IDEV
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85012
- Spectrum Medical Group
-
Phoenix, Arizona, Forenede Stater, 85006
- Southwest Center For Hiv/Aids
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72207
- Health For Life Clinic Pllc
-
-
California
-
Beverly Hills, California, Forenede Stater, 90211
- AHF Research Center
-
Costa Mesa, California, Forenede Stater, 92626
- Michael Keith Wensley, MD, Inc., A Medical Corporation
-
Long Beach, California, Forenede Stater, 90813
- Living Hope Clinical Foundation
-
Los Angeles, California, Forenede Stater, 90028
- Jeffrey Goodman Special Care Clinic
-
Los Angeles, California, Forenede Stater, 90027
- Kaiser Permanente
-
Los Angeles, California, Forenede Stater, 90069
- Anthony Mills MD Inc
-
Los Angeles, California, Forenede Stater, 90036
- Peter J Ruane, MD, Inc
-
Newport Beach, California, Forenede Stater, 92663
- Orange Coast Medical Group
-
Oakland, California, Forenede Stater, 94602
- Alameda County Medical Center
-
Oakland, California, Forenede Stater, 94609
- East Bay AIDS Center
-
Palo Alto, California, Forenede Stater, 94303
- Stanford University
-
Sacramento, California, Forenede Stater, 95817
- University of California, Davis Medical Center
-
Sacramento, California, Forenede Stater, 95825
- Kaiser Permanente Medical Group
-
San Diego, California, Forenede Stater, 92103
- La Playa Medical Group and Clinical Research
-
San Francisco, California, Forenede Stater, 94118
- Kaiser Permanente Medical Center, Clinical Trials Unit
-
San Francisco, California, Forenede Stater, 94109
- Metropolis Medical Group
-
San Leandro, California, Forenede Stater, 94577
- Kaiser Permanente Hospital
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80209
- Apex Research LLC
-
-
Connecticut
-
Greenwich, Connecticut, Forenede Stater, 06830
- Greenwich Hospital
-
New Haven, Connecticut, Forenede Stater, 06510
- Yale University HIV Clinical Trials Program
-
-
District of Columbia
-
Washington, District of Columbia, Forenede Stater, 20037
- George Washington University Medical Faculty Associates
-
Washington, District of Columbia, Forenede Stater, 20009
- Whitman Walker Clinic
-
Washington, District of Columbia, Forenede Stater, 20009
- Dupont Circle Physicians Group
-
Washington, District of Columbia, Forenede Stater, 20036
- Capital Medical Associates, PC
-
-
Florida
-
Fort Lauderdale, Florida, Forenede Stater, 33308
- Therafirst Medical Center
-
Fort Lauderdale, Florida, Forenede Stater, 33311
- Broward Health/Comprehensive Care Center
-
Fort Lauderdale, Florida, Forenede Stater, 33316
- Gary J. Richmond,M.D.,P.A.
-
Fort Pierce, Florida, Forenede Stater, 34982
- Midway Immunology and Research Center
-
Miami, Florida, Forenede Stater, 33133
- The Kinder Medical Group
-
Miami Beach, Florida, Forenede Stater, 33139
- Wohlfeiler, Piperato and Associates, LLC
-
Orlando, Florida, Forenede Stater, 32803
- Orlando Immunology Center
-
Orlando, Florida, Forenede Stater, 32806
- IDOCF/ Value Health MD, LLC
-
Tampa, Florida, Forenede Stater, 33614
- Infectious Disease Research Institute Inc.
-
Tampa, Florida, Forenede Stater, 33602
- University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department
-
Tampa, Florida, Forenede Stater, 33615
- St. Joseph's Comprehensive Research Institute
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- AIDS Research Consortium of Atlanta
-
Atlanta, Georgia, Forenede Stater, 30309
- Atlanta ID Group, PC
-
Decatur, Georgia, Forenede Stater, 30033
- Infectious Disease Specialists of Atlanta
-
Macon, Georgia, Forenede Stater, 31201
- Mercer University School of Medicine
-
-
Hawaii
-
Honolulu, Hawaii, Forenede Stater, 96816
- University of Hawaii - Hawaii Center for AIDS
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60612
- Ruth M. Rothstein CORE Center
-
Chicago, Illinois, Forenede Stater, 60613
- Howard Brown Health Center
-
Chicago, Illinois, Forenede Stater, 60657
- Northstar Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02111
- Community Research Initiative of New England
-
Springfield, Massachusetts, Forenede Stater, 01199
- Baystate Infectious Diseases Clinical Research
-
Springfield, Massachusetts, Forenede Stater, 01105
- The Research Institute
-
-
Michigan
-
Berkley, Michigan, Forenede Stater, 48072
- Be Well Medical Center
-
Detroit, Michigan, Forenede Stater, 48202
- Henry Ford Health System
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55415
- Hennepin County Medical Center
-
-
Missouri
-
Saint Louis, Missouri, Forenede Stater, 63110
- Saint Louis University
-
Saint Louis, Missouri, Forenede Stater, 63108
- Central West Clinical Research
-
Saint Louis, Missouri, Forenede Stater, 63139
- Southampton Healthcare
-
-
New Jersey
-
Hillsborough, New Jersey, Forenede Stater, 08844
- ID Care
-
Newark, New Jersey, Forenede Stater, 07102
- Saint Michaels Medical Center
-
Somers Point, New Jersey, Forenede Stater, 08244
- South Jersey Infectious Disease
-
-
New Mexico
-
Santa Fe, New Mexico, Forenede Stater, 87505
- Southwest CARE Center
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Upstate ID Association
-
Albany, New York, Forenede Stater, 12209
- Albany Medical College
-
Bronx, New York, Forenede Stater, 10461
- Jacobi Medical Center
-
Bronx, New York, Forenede Stater, 10467
- Montefiore Medical Center - AIDS Center
-
Flushing, New York, Forenede Stater, 11355
- New York Hospital Queens
-
Manhasset, New York, Forenede Stater, 11030
- North Shore University Hospital, Divison of Infectious Diseases
-
Mount Vernon, New York, Forenede Stater, 10550
- Greiger Clinic
-
New York, New York, Forenede Stater, 10011
- Chelsea Village Medical, PC
-
New York, New York, Forenede Stater, 10003
- Beth Israel Medical Center- Division of Infectious Diseases
-
New York, New York, Forenede Stater, 10011
- Ricky K. Hsu, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- University of NC AIDS Clinical Trials Unit
-
Charlotte, North Carolina, Forenede Stater, 28207
- Carolinas Medical Center-Myers Park
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Health System
-
Greenville, North Carolina, Forenede Stater, 27834
- East Carolina University
-
Huntersville, North Carolina, Forenede Stater, 28078
- Rosedale Infectious Diseases
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44304
- Summa Health System
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Thomas Jefferson University
-
-
South Carolina
-
Columbia, South Carolina, Forenede Stater, 29203
- Palmetto Health Richland
-
-
Texas
-
Dallas, Texas, Forenede Stater, 75219
- Southwest Infectious Disease Clinical Research, Inc.
-
Dallas, Texas, Forenede Stater, 75215
- AIDS Arms, Inc./ Peabody Health Center
-
Fort Worth, Texas, Forenede Stater, 76104
- Tarrant County Infectious Disease Associates
-
Harlingen, Texas, Forenede Stater, 78550
- Garcia's Family Health Group
-
Houston, Texas, Forenede Stater, 77098
- Gordon E. Crofoot MD PA
-
Houston, Texas, Forenede Stater, 77004
- Therapeutic Concepts, P.A.
-
Houston, Texas, Forenede Stater, 77098
- Research Access Network
-
Longview, Texas, Forenede Stater, 75605
- DCOL Center for Clinical Research
-
-
Virginia
-
Annandale, Virginia, Forenede Stater, 22003
- Clinical Alliance for Research & Education, Infectious Diseases (CARE-ID)
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Peter Shalit, M.D.
-
Spokane, Washington, Forenede Stater, 99202
- Premier Clinical Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forenede Stater, 53226
- Medical College of Wisconsin
-
-
-
-
-
Lyon, Frankrig, 75970
- Hôpital de La Croix Rousse
-
Nantes, Frankrig, 44093
- Chu Hotel Dieu
-
Nice, Frankrig, 06200
- Archet 1 CHU de Nice - 6ème Niveau
-
Paris, Frankrig, 75010
- Hôpital Saint louis
-
Paris, Frankrig, 75012
- Hopital Saint Antoine
-
Paris, Frankrig, 75018
- Bichat Hospital
-
Tourcoing, Frankrig, 59208
- Centre Hospitalier de Tourcoing
-
-
-
-
-
Amsterdam, Holland, 1091 AC
- Onze Lieve Vrouwe Gasthuis, Afdeling Infectieziekten
-
Rotterdam, Holland, 3000 CA
- Erasmus MC
-
-
-
-
-
Milan, Italien, 20127
- Fondazione Centro San Raffaele del Monte Tabor
-
Milano, Italien, 20157
- Azienda Ospedaliera Luigi Sacco 1° Divisione Malattie Infettive
-
Rome, Italien, 00149
- Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS
-
Torino, Italien, 10149
- Comprensorio Amedeo Di Savoia Birago Di Vische
-
-
-
-
-
Guadalajara, Mexico, 44280
- Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
-
-
-
-
-
Lisbon, Portugal, 1649-035
- Hospital de Santa Maria
-
Porto, Portugal, 4202-451
- Servico De Doencas Infecciosas - Hospital De Sao Joao
-
-
-
-
-
San Juan, Puerto Rico, 00909
- Clinical Research Puerto Rico
-
San Juan, Puerto Rico, 00909
- Hope Clinical Research
-
San Juan, Puerto Rico, 00921
- VA Caribbean Healthcare System
-
-
-
-
-
Bern, Schweiz, 3010
- Universitätsklinik für Infektiologie, Universitätsspital Bern
-
Lausanne, Schweiz, 1011
- Centre Hospitalier Universitaire Vaudois
-
Zürich, Schweiz, 8091
- University Hospital of Zürich
-
-
-
-
-
Barcelona, Spanien, 08907
- Hospital Universitari de Bellvitge
-
Madrid, Spanien, 28046
- Hospital Universitario La Paz
-
Sevilla, Spanien, 41013
- Hospital Virgen del Rocío
-
-
-
-
-
Stockholm, Sverige, 11883
- Sodersjukhuset
-
-
-
-
-
Bangkok, Thailand, 10400
- Ramathibodi Hospital, Mahidol University
-
Bangkok, Thailand, 10330
- HIV-NAT, Thai Red Cross AIDS Research Center and Faculty of Medicine Chulalongkorn University
-
Bangkok, Thailand, 10700
- Siriraj HospitalDepartment of Preventive and Social Medicine, Faculty of Medicine
-
Chiang Mai, Thailand, 50200
- Maharaj Nakorn Chiang Mai University, Faculty of Medicine, Department of Medicine
-
Khon Kaen, Thailand, 40002
- Khon Kaen University
-
-
-
-
-
Berlin, Tyskland, 12157
- EPIMED GmbH
-
Bonn, Tyskland, 53127
- University of Bonn
-
Duesseldorf, Tyskland, 40237
- Center for HIV and Hepatogastroenterology
-
Frankfurt am Main, Tyskland, 60590
- Universitatsklinikum Frankfurt
-
Frankfurt am Main, Tyskland, 60311
- Infektio Research GmbH / Infektiologikum Frankfurt
-
Freiburg, Tyskland, 79106
- Universitatsklinikum Freiburg
-
Hamburg, Tyskland, 20146
- ICH Study Center Hamburg
-
Hamburg, Tyskland, 20246
- University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit
-
Köln, Tyskland, 50937
- University of Cologne, Department of Internal Medicine
-
München, Tyskland, 80335
- MUC Research GmbH
-
-
-
-
-
Graz, Østrig, 8020
- Medizinische Universität Graz
-
Vienna, Østrig, 1090
- Medizinische Universität Wien
-
Vienna, Østrig, 1140
- SMZ Baumgartner Hoehe - Otto-Wagner-Spital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Nøgleinklusionskriterier:
- Evne til at forstå og underskrive en skriftlig informeret samtykkeformular, som skal indhentes før påbegyndelse af undersøgelsesprocedurer
- Modtager i øjeblikket antiretroviral behandling bestående af E/C/F/TDF, EFV/FTC/TDF, RTV+ATV+FTC/TDF eller COBI+ATV+FTC/TDF i ≥ 6 på hinanden følgende måneder forud for det sidste besøg i deres tidligere undersøgelse
- Afslutning af besøget i uge 144 i undersøgelserne GS-US-236-0102, GS-US-236-0103, GS-US-216-0114 eller afslutningen af besøget i uge 96 i undersøgelsen GS-US-264-0110 (kun deltagere på et EFV-baseret regime), eller færdiggørelse af undersøgelser GS-US-236-0104, GS-US-216-0105
- Koncentrationer af humant immundefektvirus type 1-ribonukleinsyre (HIV-1 RNA) i plasma ved upåviselige niveauer i mindst 6 på hinanden følgende måneder forud for screeningsbesøget og har HIV RNA < 50 kopier/ml ved screeningsbesøget
- Normal ekkokardiograf (EKG)
- Estimeret glomerulær filtrationshastighed (GFR) ≥ 50 ml/min i henhold til Cockcroft-Gault-formlen for kreatininclearance
- Levertransaminaser (aspartataminotransferase [AST] og alaninaminotransferase [ALT]) ≤ 5 × øvre grænse for normalområdet (ULN)
- Direkte bilirubin ≤ 1,5 x ULN
- Tilstrækkelig hæmatologisk funktion
- Serumamylase ≤ 5 × ULN
- Kvinder i den fødedygtige alder skal acceptere at bruge højeffektive præventionsmetoder eller være ikke-heteroseksuelt aktive eller praktisere seksuel afholdenhed fra screening under hele undersøgelsesbehandlingens varighed og i 12 uger efter den sidste dosis af undersøgelseslægemidlet, hvis de får EFV/FTC/TDF-regimen. og 30 dage for dem, der er tildelt alle andre regimer.
- Kvindelige deltagere, der bruger hormonelle præventionsmidler som en af deres præventionsmetoder, skal have brugt den samme metode i mindst tre måneder før undersøgelsesdosering
- Kvindelige deltagere, der er stoppet med menstruation i ≥ 12 måneder, men ikke har dokumentation for hormonsvigt i æggestokkene, skal have et serum follikelstimulerende hormon (FSH) niveau ved screening inden for det postmenopausale område baseret på Central Laboratory referenceområde
Nøgleekskluderingskriterier:
- En ny erhvervet immundefektsyndrom (AIDS)-definerende tilstand diagnosticeret inden for de 30 dage før screening
- Hepatitis B overfladeantigenposition
- Hepatitis C antistof positiv
- Deltagere, der oplever dekompenseret cirrhose
- Kvinder, der ammer
- Positiv serum graviditetstest
- Få en implanteret defibrillator eller pacemaker
- Nuværende alkohol- eller stofbrug vurderet af investigator til potentielt at interferere med forsøgspersonens overholdelse
- Anamnese med malignitet inden for de seneste 5 år eller igangværende malignitet bortset fra kutant Kaposis sarkom, basalcellecarcinom eller resekeret, ikke-invasivt kutant pladecellekarcinom
- Aktive, alvorlige infektioner (bortset fra HIV-1-infektion), der kræver parenteral antibiotika- eller antifungal behandling inden for 30 dage før baseline
- Enhver anden klinisk tilstand eller tidligere behandling, der efter investigatorens mening ville gøre forsøgspersonen uegnet til undersøgelsen eller ude af stand til at overholde doseringskravene
- Deltagelse i ethvert andet klinisk forsøg uden forudgående godkendelse fra sponsoren er forbudt under deltagelse i dette forsøg
- Deltagere, der modtager igangværende behandling med lægemidler, der ikke skal bruges sammen med elvitegravir (EVG), COBI, FTC, TDF, ATV, RTV, EFV og TAF eller deltagere med kendte allergier over for hjælpestofferne E/C/F/TDF, E/ C/F/TAF, EFV/FTC/TDF, ATV, COBI, RTV eller FTC/TDF
Bemærk: Andre protokoldefinerede inklusions-/eksklusionskriterier kan være gældende.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: E/C/F/TAF
Randomiseret fase: Elvitegravir/cobicistat/emtricitabin/tenofoviralafenamid (E/C/F/TAF) i op til 96 uger. Forlængelsefase: Efter at have afsluttet 96 ugers randomiseret behandling, vil alle deltagere få mulighed for at modtage open-label E/C/F/TAF, indtil det bliver kommercielt tilgængeligt, eller indtil Gilead vælger at stoppe udviklingen af E/C/F /TAF. |
150/150/200/10 mg FDC tablet indgivet oralt én gang dagligt
Andre navne:
|
Aktiv komparator: Bliv på baseline behandlingsregimen (SBR)
Randomiseret fase: Deltagerne forblev på deres baseline emtricitabin (FTC)/tenofovirdisoproxilfumarat (TDF)-holdigt regime E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boostet atazanavir (ATV)+FTC/TDF; eller cobicistat (COBI-boostet ATV+FTC/TDF) administreret i henhold til ordinationsinformation i op til 96 uger. Forlængelsefase: Efter at have afsluttet 96 ugers randomiseret behandling (SBR), vil alle deltagere få mulighed for at modtage open-label E/C/F/TAF, indtil det bliver kommercielt tilgængeligt, eller indtil Gilead vælger at stoppe udviklingen af E/ C/F/TAF. |
150/150/200/300 mg FDC tablet indgivet oralt én gang dagligt
Andre navne:
200/300 mg tablet indgivet oralt én gang dagligt
Andre navne:
600/200/300 mg FDC tablet indgivet oralt én gang dagligt
Andre navne:
100 mg tablet indgivet oralt én gang dagligt
Andre navne:
300 mg kapsel indgivet oralt én gang dagligt
Andre navne:
150 mg tablet indgivet oralt én gang dagligt
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Procentdel af deltagere med HIV-1 RNA < 50 kopier/ml i uge 48
Tidsramme: Uge 48
|
Procentdelen af deltagere, der opnåede HIV-1 RNA < 50 kopier/ml i uge 48, blev analyseret ved hjælp af snapshot-algoritmen, som definerer en patients virologiske responsstatus ved kun at bruge den virale belastning på det foruddefinerede tidspunkt inden for et tilladt tidsrum, sammen med studiets ophørsstatus.
|
Uge 48
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Ændring fra baseline i serumkreatinin i uge 48
Tidsramme: Baseline; Uge 48
|
Baseline; Uge 48
|
|
Procentdel af deltagere med HIV-1 RNA < 50 kopier/ml i uge 96
Tidsramme: Uge 96
|
Procentdelen af deltagere, der opnåede HIV-1 RNA < 50 kopier/ml i uge 96, blev analyseret ved hjælp af snapshot-algoritmen, som definerer en patients virologiske responsstatus ved kun at bruge virusbelastningen på det foruddefinerede tidspunkt inden for et tilladt tidsrum, sammen med studiets ophørsstatus.
|
Uge 96
|
Procent ændring fra baseline i hofteknoglemineraldensitet (BMD) i uge 48
Tidsramme: Baseline; Uge 48
|
Hofte BMD blev vurderet ved dobbelt energi røntgen absorptiometri (DXA) scanning.
BMD beregnes som gram pr. kvadratcentimeter (g/cm^2); den gennemsnitlige (SD) procentvise ændring vises.
|
Baseline; Uge 48
|
Procentvis ændring fra baseline i rygsøjlens BMD i uge 48
Tidsramme: Baseline; Uge 48
|
Rygsøjlens BMD blev vurderet ved DXA-scanning.
BMD beregnes som g/cm^2; den gennemsnitlige (SD) procentvise ændring vises.
|
Baseline; Uge 48
|
Ændring fra baseline i den samlede EFV-relaterede symptomvurderingsscore i uge 48
Tidsramme: Baseline; Uge 48
|
Den gennemsnitlige (SD) ændring af den samlede EFV-relaterede symptomvurderingsscore er præsenteret. Den overordnede symptomscore (spænder fra 0 til 20) er summen af de individuelle symptomscore, der spænder fra 0 (ingen symptomer) til 4 (mest alvorlige symptomer) fra de 5 EFV-relaterede symptomvurderinger (svimmelhed, søvnbesvær, nedsat koncentrationsevne, søvnighed og unormale eller livlige drømme). En negativ ændring fra baseline indikerer forbedring. EFV-relateret symptomanalysesæt: deltagere, der modtog EFV/FTC/TDF som tidligere behandling, modtog mindst 1 dosis af undersøgelseslægemidlet og gennemførte EFV-relaterede symptomvurderinger ved baselinebesøget og mindst 1 postbaselinebesøg. |
Baseline; Uge 48
|
Procentdel af deltagere med HIV-1 RNA < 20 kopier/ml i uge 48
Tidsramme: Uge 48
|
Procentdelen af deltagere, der opnåede HIV-1 RNA < 20 kopier/ml i uge 48, blev analyseret ved hjælp af snapshot-algoritmen, som definerer en patients virologiske responsstatus ved kun at bruge virusbelastningen på det foruddefinerede tidspunkt inden for et tilladt tidsrum, sammen med studiets ophørsstatus.
|
Uge 48
|
Procentdel af deltagere med HIV-1 RNA < 20 kopier/ml i uge 96
Tidsramme: Uge 96
|
Procentdelen af deltagere, der opnåede HIV-1 RNA < 20 kopier/ml i uge 96, blev analyseret ved hjælp af snapshot-algoritmen, som definerer en patients virologiske responsstatus ved kun at bruge den virale belastning på det foruddefinerede tidspunkt inden for et tilladt tidsrum, sammen med studiets ophørsstatus.
|
Uge 96
|
Ændring fra baseline i klyngedeterminant 4 (CD4) celletælling i uge 48
Tidsramme: Baseline; Uge 48
|
Analysen af CD4-celletal inkluderede værdier op til 1 dag efter sidste dosisdato af randomiseret undersøgelseslægemiddel. Ændringen fra baseline i CD4-celletal for det fulde analysesæt var baseret på observerede data (dvs. Manglende = udelukket) for det samlede antal og ved det tidligere behandlingsregime.
|
Baseline; Uge 48
|
Ændring fra baseline i CD4-celletal i uge 96
Tidsramme: Baseline; Uge 96
|
Analysen af CD4-celletal inkluderede værdier op til 1 dag efter sidste dosisdato af randomiseret undersøgelseslægemiddel. Ændringen fra baseline i CD4-celletal for det fulde analysesæt var baseret på observerede data (dvs. Manglende = udelukket) for det samlede antal og ved det tidligere behandlingsregime.
|
Baseline; Uge 96
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B, de Wet J, Rockstroh J, Lazzarin A, Rijnders B, Podzamczer D, Thalme A, Stoeckle M, Porter D, Liu HC, Cheng A, Quirk E, SenGupta D, Cao H. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Lancet HIV. 2017 May;4(5):e195-e204. doi: 10.1016/S2352-3018(17)30031-0. Epub 2017 Mar 2.
- Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223.
- Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, Stephens JL, Girard PM, Huhn G, Plummer A, Liu YP, Cheng AK, McCallister S; GS-US-292-0109 team. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016 Jan;16(1):43-52. doi: 10.1016/S1473-3099(15)00348-5. Epub 2015 Nov 2.
- Brown T, Yin MT, Gupta S, Katlama C, et al. Switching from TDF to TAF in HIV-infected adults with low BMD: a pooled analysis. 24th Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2017; poster presentation: abstract #683.
- Podzamczer D, Viciana P, Rijnders B, Shalit P, et al. Switching from Tenofovir disoproxil fumarate to tenofovir alafenamide in patients with high risk for chronic kidney disease. 8th National Congress of the AIDS Study Group (GESIDA) and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) held jointly with the 9th Teacher Meeting of AIDS Research Network 2016; poster presentation: abstract #P-188.
- Orkin C, Rjinders B, Stephan C, McKellar M, et al. Switching from boosted atazanavir (ATV) plus FTC/TDF to a TAF-based single tablet regimen (STR): Week 48 data in virologically suppressed adults. Annual Conference of the British Association for Sexual Health and HIV (BASHH) 2016; poster presentation: abstract # P045.
- Mills A, Andrade J, Koenig E, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 13th Congress for Infectious Diseases and Tropical Medicine (KIT) 2016; poster presentation: abstract #eP-038.
- Overton ET, Shalit P, Crofoot G, Benson P, et al. Switch from TDF regimens to E/C/F/TAF is associated with improved bone mineral density (BMD), decreased serum PTH and decreased bone turnover biomarkers. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; poster presentation: abstract #PW-027.
- Huhn G, Rijnders B, Thompson M, Tebas P, et al. Switching from TDF to TAF in patients with high risk for CKD. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; oral presentation: https://www.natap.org/2016/HIV/062116_01.htm.
- Abram M, Margot NA, Cox S, Ram RR, et al. Pooled week-48 analysis of HIV-1 drug resistance in E/C/F/TAF (Genvoya) phase 3 studies. 23rd Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2016, poster presentation: abstract #496.
- Abram M, Margot NA, Cox S, Ram RR, et al. Pooled week-48 analysis of HIV-1 drug resistance in E/C/F/TAF (Genvoya) phase 3 studies. 25th International HIV Drug Resistance Workshop - Informed Horizons, LLC 2016; poster presentation: abstract #33.
- Mills A, Andrade J, Di Perri G, Van Lunzen J, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 8th Biennial Conference on HIV Pathogenesis and Treatment and Prevention of the International AIDS Society (IAS) 2015; oral presentation: abstract #TUAB0102.
- Shamblaw D, Van Lunzen J, Orkin C, Bloch M, eta al. Switching from Atripla (ATR) to a tenofovir alafenamide (TAF)-based single tablet regimen: week 48 data in virologically suppressed adults. 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2015; oral presentation; https://natap.org/2015/ICAAC/ICAAC_13.htm.
- Thompson M, Morales-Ramirez J, Mcdonald C, Rachlis A, et al. Switching from a tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): Week 48 data in HIV-1 infected virologically suppressed adults. Spring Conference of the Society for Healthcare Epidemiology of America (SHEA) 2015; oral presentation: abstract #725.
- Rijnders B, Stephan C, Lazzarin A, Squires K, et al. Switching from ritonavir or cobicistat boosted atazanavir (ATV) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) to a tenofovir alafenamide (TAF)-based single tablet regimen (STR): week 48 data in virologically suppressed adults. 15th European AIDS Conference (EACS) and 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV 2015; poster presentation: abstract #577.
- Lutz T, Benson P, Goffard J-C, Haubrich R, et al. Patient reported outcomes (PRO) over 48 weeks in a randomized, open-label trial of patients with HIV switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF). 15th European AIDS Conference (EACS) and 17th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV 2015; poster presentation: abstract #324.
- Viciana P, Mills A, Andrade J, Diperri G, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: data in virologically suppressed adults through 48 weeks of treatment. 7th National Congress of the AIDS Study Group (GESIDA) and Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) held jointly with the 8th Teacher Meeting of AIDS Research Network 2015; oral presentation: abstract #PO-08.
- Mills A, Andrade-Villanueva J, DiPerri G, Van Luzen J, et al. Switching from a tenofovir disoproxil fumarate (TDF)-based regimen to a tenofovir alafenamide (TAF)-based regimen: Data in virologically suppressed adults through 48 weeks of treatment. 8th Annual International AIDS Society meeting 2015; oral presentation: abstract #839.
- Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide vs tenofovir DF in women: pooled analysis of 7 clinical trials. Annual Meeting of the American Pharmacists Association (APhA) - Virtual 2020; poster presentation: abstract #209.
- Stellbrink H, Gandhi-Patel B, Zhong L, Das M, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. Annual Meeting of the American Pharmacists Association (APhA) - Virtual 2020; poster presentation: abstract #205.
- Stellbrink H-J, Post FA, Podzamczer D, Arribas J, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. 15th Congress on Infectious Diseases and Tropical Medicine - German Society for Infectious Diseases (DPID) held jointly with the 29th Annual Meeting of the German Society for Pediatric Infectiology (DGPI) 2020; poster presentation: abstract #A-343.
- Hermansson L, Yilmaz A, Price RW, Nilsson S, McCallister S, Makadzange T, Das M, Zetterberg H, Blennow K, Gisslen M. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS One. 2019 Dec 11;14(12):e0226276. doi: 10.1371/journal.pone.0226276. eCollection 2019.
- Stellbrink H-J, Post FA, Podzamczer D, Arribas J, et al. Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. 17th European AIDS Conference of the European AIDS Clinical Society (EACS) 2019; poster presentation: abstract #PE9-50.
- Pepperrell T, Hughes S, Gotham D, Pozniak A, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate - is there a true difference in safety? 17th European AIDS Conference of the European AIDS Clinical Society (EACS) 2019; poster presentation: abstract #PE3-8.
- Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide vs. tenofovir DF in women: pooled analysis of 7 clinical trials. 9th Edition International Workshop on HIV and Women - Virology Education 2019; poster presentation: abstract #21.
- Dejesus E, Federico Andrade Villanueva J, Ramon Arribas Lopez J, Brinson C, et al. Tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in hispanic/latinx and black participants: efficacy, bone and renal safety results from a pooled analysis of 7 clinical trials. IDWeek Meeting of the Infectious Diseases Society of America (IDSA) 2019; poster presentation: abstract #318.
- Walmsley S, Andany N, Brar I, Brinson C, et al. Tenofovir alafenamide VS tenofovir DF in women: pooled analysis of 7 clinical trials. 28th Annual Canadian Conference on HIV/AIDS Research - Canadian Association for HIV Research (CAHR) 2019; poster presentation: abstract #CSP9.04.
- Kim YS, Oka S, Chetchotisakd P, Clarke A, Supparatpinyo K, Avihingsanon A, Ratanasuwan W, Kiertiburanakul S, Ruxrungtham K, Yang S, Guo S, Liu Y, Das M, Tran D, McColl D, Corales R, Nguyen C, Piontkowsky D. Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials. HIV Res Clin Pract. 2019 Jul 8:1-9. doi: 10.1080/15284336.2019.1589232. Online ahead of print.
- Hermansson L, Price RW, Yilmaz A, Nilsson S, et al. Effect on plasma NFL, a marker or neuronal injury, after switching from TDF to TAF. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2019; oral presentation: abstract #127.
- Thompson M, Brar I, Brinson C, Creticos C, et al. Tenofovir alafenamide VS tenofovir DF in women: pooled analysis of 7 clinical trials. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2019; poster presentation: abstract #519.
- Orkin C, Castelli F, Yazdanpanah Y, Rockstroh J, et al. Cardiovascular disease risk assessments and fasting lipid changes in virologically suppressed patients randomized to switch to tenofovir alafenamide versus continuing tenofovir disoproxil fumarate. 22nd International AIDS Conference - International AIDS Society 2018; poster presentation: abstract #TUPEB104.
- Brown TT, Yin MT, Gupta SK, Short WR, et al. Combined effects of bisphosphonates & TDF->TAF switch in HIV+ adults with low BMD. Annual Conference on Retroviruses and Opportunistic Infections (CROI) - CROI Foundation 2018; poster presentation: abstract #724.
- DeJesus E, Haas B, Segal-Maurer S, Ramgopal MN, Mills A, Margot N, Liu YP, Makadzange T, McCallister S. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. AIDS Res Hum Retroviruses. 2018 Apr;34(4):337-342. doi: 10.1089/AID.2017.0203. Epub 2018 Mar 20.
- Goldstein D, Ward D, Brinson C, Crofoot G, et al. Week 96 efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in older, HIV-Infected virologically-suppressed adults. Annual Meeting of the American Geriatrics Society (AGS) 2017; poster presentation: abstract #A90.
- Ward D, Thompson M, Goldstein D, Brinson C, et al. Week 96 efficacy and safety of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in older, HIV-infected treatment-naïve adults. Annual Meeting of the American Geriatrics Society (AGS) 2017; poster presentation: abstract #A91.
- Choe S, Podzamvzer D, Tashima K, McNicholl I, and McCallister S. Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI). Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP) 2017; poster presentation: abstract #7-068.
- Yin M, Gupta S, Nguyen-Cleary T, Mora M, and Das M. Switching from TDF to TAF in HIV-infected adults with low BMD: A pooled analysis. Congress on HIV and Hepatitis in the Americas - ViiV Healthcare UK Limited 2017; poster presentation: abstract #P021.
- Podzamczer D, Tashima K, Daar E, McGowan J, et al. Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI). International Congress of Drug Therapy in HIV Infection - International AIDS Society 2016; poster presentation: abstract #P314.
- Dejesus E, Haas B, Segal-Maurer S, Ramgopal M, et al. Superior efficacy and improved renal and bone safety after switching from a tenofovir disoproxil fumarate (TDF) regimen to a tenofovir alafenamide (TAF) based regimen through 96 weeks (W96) of treatment. 56th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held Jointly with the 2016 Annual Meeting on Microbe - American Society for Microbiology (ASM) 2016; poster presentation: abstract # LB-087.
- Viciana P, Rijnders B, Shalit P, Liu Y et al. Cambio desde TDF a TAF en pacientes en alto riesgo de erc. 18th Congress of the Andalusian Society of Infectious Diseases (SAID) 2016; poster presentation: abstract #P-070.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- HIV-infektioner
- Anti-infektionsmidler
- Antivirale midler
- Anti-HIV-midler
- Anti-retrovirale midler
- Elvitegravir, Cobicistat, Emtricitabin, Tenofovir Disoproxil Fumarate Lægemiddelkombination
Andre undersøgelses-id-numre
- GS-US-292-0109
- 2012-005114-20 (EudraCT nummer)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
IPD-delingsadgangskriterier
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-infektioner
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universidad del DesarrolloAfsluttetHealthcare Associated InfectionChile
-
The University of Texas Health Science Center,...EurofinsAfsluttetOdontogen Deep Space Neck InfectionForenede Stater
-
Imelda Hospital, BonheidenAfsluttetHealthcare Associated InfectionBelgien
-
University of PennsylvaniaAfsluttetAntimikrobiel resistensForenede Stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentAfsluttetMenneskelig mikrobiomForenede Stater
-
Universidad Autonoma de Nuevo LeonUkendtSundhedsrelaterede infektioner
-
Centre Hospitalier Universitaire de NīmesRekrutteringÆldre | Healthcare Associated InfectionFrankrig
-
Centre Hospitalier Universitaire, AmiensAfsluttetHealthcare Associated Infection | IglerFrankrig
Kliniske forsøg med E/C/F/TAF
-
Gilead SciencesAfsluttetHIV-infektioner | HIVForenede Stater, Det Forenede Kongerige, Sverige, Frankrig, Puerto Rico, Holland, Italien, Portugal, Canada, Mexico, Dominikanske republik
-
Gilead SciencesAfsluttetHIV-infektioner | Erhvervet immundefektsyndromForenede Stater, Puerto Rico
-
Gilead SciencesAfsluttetHIV-infektioner | HIVForenede Stater, Spanien, Schweiz, Canada, Thailand, Puerto Rico, Australien, Østrig, Belgien, Italien, Japan, Det Forenede Kongerige
-
Gilead SciencesAktiv, ikke rekrutterendeHIV-infektioner | Erhvervet immundefektsyndrom (AIDS)Forenede Stater, Thailand, Uganda, Sydafrika, Zimbabwe
-
Gilead SciencesIkke rekrutterer endnu
-
Gilead SciencesAfsluttetHIV-1 infektionDen Russiske Føderation, Forenede Stater, Thailand, Uganda, Puerto Rico, Dominikanske republik
-
Gilead SciencesAfsluttetHIV-1 infektionForenede Stater, Frankrig, Østrig, Tyskland
-
Technical University of MunichAfsluttet
-
Gilead SciencesAfsluttetHIV-infektioner | Erhvervet immundefektsyndromForenede Stater, Thailand, Frankrig, Uganda, Det Forenede Kongerige, Belgien, Portugal, Mexico, Dominikanske republik, Italien, Puerto Rico, Den Russiske Føderation
-
Janssen Scientific Affairs, LLCAfsluttet